Comprehensive Pharmacogenetics
The Affymetrix® Drug Metabolizing Enzymes and Transporters (DMET) Early Access solution is the world's most comprehensive method for assaying the genetics of drug metabolism. The DMET solution profiles 1,069 drug metabolism biomarkers and automatically interprets data into a commonly used format that can be integrated into clinical trial workflows. The information enables researchers to make more informed drug development decisions, which in turn significantly streamlines the drug development process and time to market.
Content
DMET is the only product available with comprehensive coverage of all ADME drug metabolism biomarkers, including common and rare variations, insertions, deletions, copy number, triallelic SNPs and pseudogenes—many of which are not assayed by conventional microarray SNP methods.
The panel includes 172 core markers that were selected in collaboration with pharmaceutical companies. These core markers have been demonstrated in literature to have a known effect on drug metabolism. Allelic frequencies for the core markers on DMET are below 0.09 on average, meaning that many of these key variants cannot be adequately interrogated by a common SNP or tagging approach that interrogate markers with an average MAF typically at ~0.2.
For added details on DMET Early Access, including a complete list of all biomarkers assayed, please contact DMET@affymetrix.com or your account representative.
Data Analysis
The DMET solution features easy-to-use patient consent and translation software to convert the core markers into a more conventional format—known as star nomenclature—that is routinely used in the genetic analyses of clinical trials. The automated analysis takes only a few minutes to complete and provides pharmaceutical researchers performing clinical trials with familiar data that can be easily integrated into existing workflows.
DMET genotyping software enables single-sample processing by relying on preset and analytically validated cluster boundaries established for each of the DMET variants. Synthetic controls for all validated markers reassure correct genotyping of rare alleles.
Availability
The DMET solution is available as a service through Affymetrix' South San Francisco Services Laboratory, Cogenics and Expression Analysis. These providers have successfully completed a six-week training and certification program to ensure that data is complete, accurate and reproducible. Cogenics and Expression Analysis are offering the DMET service as a Good Laboratory Practice (GLP) service, while Affymetrix' South San Francisco facility is running the service strictly for non-GLP research studies.
Customer References
"Being able to measure a variety of ‘core’ genetic markers is critical to delivering accurate clinical assays, something the Affymetrix technology is allowing us to achieve. Accurate clinical assays have the ability to deliver improved patient outcomes because the medicines we develop become more directly targeted to the patient's specific needs. We are implementing this technology across the research portfolio in all phases of clinical trials at Lilly."
--Richard Deane Hockett, Senior Clinical Research Physician, Group Leader for Genomic Medicine, Department of Diagnostic and Experimental Medicine at Eli Lilly & Co
"The DMET panel has allowed us to better delineate the stable therapeutic dose of Warfarin for our patients at the initiation of therapy, where risk of complications from the drug are at their highest. Our hope is that these studies will enable us to reduce the overall complications of Warfarin therapy by a better prediction of stable therapeutic dose."
--Michael Caldwell, M.D., Ph.D., Director, Wound Healing Program at Marshfield Clinic
Recent Publications
Additional Information
If you're interested in more information on DMET Early Access and how to order, please contact DMET@affymetrix.com. |
